RTP Mobile Logo
RTP TV: Part VI — Triple-Negative Breast Cancer (TNBC): Current Clinical Management
Released July 2011

The sixth seminar of our eight-part online, integrated educational course explores topics relevant to the treatment of TNBC. Originally held on July 19, 2011, Part VI features Drs Harold J Burstein and Charles E Geyer Jr. (Webinar)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

    OVERVIEW OF ACTIVITY

    TNBC represents a more aggressive, higher-risk phenotype with an increased incidence of distant recurrence and death compared to other types of breast cancer. Despite an overall increase in knowledge of the biologic and natural history of TNBC, inadequate effective therapies for this patient subset persist. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematology-oncology fellows and other healthcare providers must be well informed of these advances. This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians with the incorporation of newly published data into best-practice breast cancer treatment algorithms.

    LEARNING OBJECTIVES

    • Develop a therapeutic algorithm for the evidence-based management of TNBC.
    • Counsel appropriately selected patients about availability of and participation in ongoing clinical research studies focusing on the management of early and advanced TNBC.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    Charles E Geyer Jr, MD
    Director of Medical Affairs
    National Surgical Adjuvant Breast and Bowel Project
    Vice-Chair, Department of Human Oncology
    Allegheny General Hospital
    Pittsburgh, Pennsylvania

    No real or apparent conflicts of interest to disclose.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2011
    Expiration date: July 2012

     

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):